Lever
Lifestyle
- Maintain healthy blood pressure
- Regular physical activity
- Adequate hydration
Blutwerte · Marker
eGFR
Estimated GFR · Glomeruläre Filtrationsrate · GFR · CKD-EPI
Nierenwerte
- Einheit:
- mL/min/1.73 m2
The eGFR test quantifies the estimated rate of blood filtration by the kidneys, calculated from serum creatinine levels.
Reference Ranges
Reference
60–120mL/min/1.73 m2
60
120
LowNormalHigh
Reference
Unit · mL/min/1.73 m2Reference ranges may vary based on age, sex, and ethnicity. Values below 60 mL/min/1.73 m2 typically indicate CKD.
Overview
Übersicht
Estimated Glomerular Filtration Rate (eGFR) is a blood test that estimates the rate at which the kidneys filter waste from the blood, providing a measure of kidney function. It is calculated using serum creatinine levels, age, sex, and sometimes race, reflecting the kidneys' ability to filter blood effectively. Clinically, eGFR is crucial for diagnosing and monitoring chronic kidney disease (CKD) and assessing kidney function in various medical conditions. Researchers have found that a decline in eGFR is associated with the progression of kidney disease, and it is used as a surrogate endpoint in clinical trials for CKD. For athletes and biohackers, maintaining optimal kidney function is important for overall health and performance, as kidney health can influence hydration status, electrolyte balance, and toxin clearance. However, factors such as muscle mass, diet, and hydration can affect creatinine levels, potentially confounding eGFR results. It is important to consider these factors when interpreting eGFR, and testing should ideally be done under consistent conditions to ensure accuracy.
Klinische Bedeutung
Elevated eGFR values generally indicate normal or hyperfiltration states, while reduced eGFR values suggest impaired kidney function, often associated with chronic kidney disease or acute kidney injury.
Dynamics
Trend Interpretation
Rising Values
Progressively rising eGFR values may indicate hyperfiltration, often seen in early diabetes or high blood pressure. Re-test recommended in 3-6 months.
Falling Values
Progressively falling eGFR values suggest worsening kidney function, warranting further investigation and monitoring.
Re-test Interval
6 months if outside optimal range
Etiology
Causes — High & Low
Cause
Elevated Levels
- High protein intake
- Increased muscle mass
- Pregnancy
- Hyperfiltration states
Cause
Low Levels
- Chronic kidney disease
- Acute kidney injury
- Dehydration
- Heart failure
Protocol
How to Optimize
Lever
Nutrition
- Reduce sodium intake
- Limit protein to recommended levels
Note:
Consult a healthcare provider before making significant dietary or lifestyle changes, especially if kidney disease is suspected.
Testing Guidelines
✓Fasting Not Required
✓Not Time-Sensitive
Testing Frequency
Annually for healthy adults, more frequently if at risk for kidney disease
Interfering Factors
- High meat intake
- Intense exercise
- Dehydration
Open Research Questions
Current research suggests that the impact of estimated glomerular filtration rate (eGFR) on blood biomarkers for Alzheimer's disease remains debated, particularly regarding its confounding effects and the significance of associations after adjusting for age and sex. Researchers have not yet established optimal eGFR reference ranges for diverse populations or its role in enhancing predictive models for amyloid-β positivity. Unanswered clinical questions include the extent to which eGFR influences biomarker interpretation in early-stage chronic kidney disease.
21 Research Publications
8,437
Total Citations
8
Human/RCT
89.5
Avg. Influence
2026
Latest
Sort
Filter
01Top
#01
Revised equations for estimated GFR from serum creatinine in Japan.
HumanInfluence433.0
6035
Researchers developed new equations to estimate glomerular filtration rate (eGFR) specifically for the Japanese population, addressing limitations of previous equations. The new equations showed improved accuracy and reduced bias compared to earlier models. This study emphasizes the need for tailored eGFR estimation methods based on population-specific factors.
02Top
#02
Biomarker analyses and final overall survival results from a phase III, randomized, open-label, first-line study of gefitinib versus carboplatin/paclitaxel in clinically selected patients with advanced non-small-cell lung cancer in Asia (IPASS).
HumanInfluence67.0
1560
Researchers analyzed the overall survival outcomes of patients with advanced non-small-cell lung cancer based on their epidermal growth factor receptor (EGFR) mutation status. They found no significant difference in survival between treatments with gefitinib and carboplatin/paclitaxel overall, but noted that EGFR mutations were strong predictors of progression-free survival. The study highlighted the complexity of treatment responses based on biomarker status.
03Top
#03
Change in Albuminuria and GFR as End Points for Clinical Trials in Early Stages of CKD: A Scientific Workshop Sponsored by the National Kidney Foundation in Collaboration With the US Food and Drug Administration and European Medicines Agency.
Meta-AnalysisInfluence27.0
457
This study examined the use of changes in albuminuria and estimated GFR (eGFR) as potential endpoints in clinical trials for chronic kidney disease (CKD). Researchers found that both early changes in albuminuria and eGFR slope could serve as surrogate endpoints, with stronger support for eGFR. The study highlighted the importance of understanding the conditions under which these measures are effective.
04
#04
Consensus for EGFR mutation testing in non-small cell lung cancer: results from a European workshop.
UnknownInfluence8.0
288
This workshop aimed to establish consensus on EGFR mutation testing in non-small cell lung cancer (NSCLC). Researchers found that standardization of testing methods and timely results are crucial for optimizing the use of EGFR-targeted therapies. The study emphasized the need for collaboration among healthcare professionals to enhance testing practices.
05
#05
Targeted Inhibitors of EGFR: Structure, Biology, Biomarkers, and Clinical Applications.
ReviewInfluence1.0
49
This study provided an overview of targeted inhibitors of EGFR and their clinical applications in cancer therapy. Researchers highlighted the mechanisms of resistance to EGFR-targeted drugs and the importance of personalized predictive approaches. The study aimed to improve the efficacy of these therapies through better understanding of tumor biology.
06
#06
The impact of kidney function on Alzheimer's disease blood biomarkers: implications for predicting amyloid-β positivity.
HumanInfluence1.0
26
This study evaluated the relationship between kidney function, measured by eGFR, and blood biomarkers for Alzheimer's disease (AD). Researchers found that while kidney function was associated with certain AD biomarkers, these associations diminished after adjusting for age and sex. The study concluded that eGFR does not significantly enhance the prediction of amyloid-β positivity in clinical settings.
07
#07
Occupy EGFR.
Unknown
9
This study explored the effectiveness of EGFR inhibitors in treating non-small cell lung cancer (NSCLC) and glioblastoma. Researchers found that certain inhibitors only partially occupied mutant EGFR sites in glioblastoma, indicating limited efficacy. This highlights the need for alternative inhibitors that target different receptor conformations.
08
#08
Cytokine and epigenetic regulation of CEACAM6 mediates EGFR-driven signaling and drug response in lung adenocarcinoma.
Unknown
6
09
#09
The expression and clinical significance of STAMBP in breast cancer.
Li Lei, et al. · Molecular biology reports · 2023
In Vitro
3
Researchers found that a protein called STAMBP is more abundant in breast cancer cells compared to normal cells. Higher levels of STAMBP are linked to more aggressive tumor characteristics and poorer survival rates for patients. This suggests that STAMBP could be an important marker for tracking breast cancer progression.
Key findings
- 01STAMBP protein levels are significantly higher in breast cancer tumor cells compared to noncancerous tissues.
- 02Increased STAMBP expression is associated with larger tumors and more advanced cancer stages.
- 03Reducing STAMBP levels in cancer cells decreases their ability to move and invade other tissues.
10
#10
Association of Estimated GFR Slope and Heart Failure Progression in Older Adults.
Human
2
Researchers examined the relationship between eGFR slope and heart failure progression in older adults. They found that a steeper decline in eGFR was associated with a higher risk of developing heart failure, particularly in individuals with existing cardiac abnormalities. The study suggests that monitoring eGFR slope may help identify older adults at increased risk for heart failure.
Publication Trend
Research publications about eGFR over time
6totalTrack your bloodwork in PepStack
Log lab results, track trends and optimize your biomarkers over time.
Legal Disclaimer
This page is for informational and research purposes only. All information is based on published scientific literature and does not constitute medical advice, diagnosis, or treatment recommendations. Many substances listed may not be approved for human use and may be subject to drug regulation laws (e.g., AMG in Germany, FDA in the US). PepStack does not encourage the use of any substance on humans. Always consult a qualified healthcare professional before making any health-related decisions. Use of this information is entirely at your own risk. PepStack assumes no liability for the accuracy, completeness, or timeliness of the content provided. Full disclaimer